{"entity":{"id":"geneoscopy","kind":"company","name":"Geneoscopy","aka":["ColoSense"],"tldr":"A St. Louis diagnostics company whose ColoSense stool RNA test became, in 2024, the first RNA-based colorectal cancer screening test approved in the United States.","summary":"Geneoscopy was founded by Washington University alumni to develop diagnostics from RNA shed by cells of the gut lining into stool. Its first product, ColoSense, combines eight RNA markers with a faecal immunochemical test for blood and was approved by the FDA in May 2024 for colorectal cancer screening in average-risk adults aged 45 and over, on the strength of the CRC-PREVENT study. The company positions stool RNA as less prone to the age-related false positives of stool DNA methylation tests and is developing further gut RNA tests, including for inflammatory bowel disease.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.geneoscopy.com"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["multitarget-stool-rna-test","colorectal-screening","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"St. Louis, Missouri, United States","country":"US","companyType":"diagnostics","website":"https://www.geneoscopy.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/geneoscopy/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/"},{"id":"multitarget-stool-rna-test","kind":"technology","name":"Multitarget stool RNA test (ColoSense)","route":"/technologies/multitarget-stool-rna-test/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}]}}